

# JOURNAL OF CLINICAL ONCOLOGY

Official Journal of the American Society of Clinical Oncology

Vol 27, No 26

C O N T E N T S

September 10, 2009

## Editorials

### Secondary Breast Cancer in Hodgkin's Lymphoma Survivors

Michael Crump and David Hodgson (see article on page 4239) ..... 4229

### EML4-ALK: Honing In on a New Target in Non-Small-Cell Lung Cancer

Leora Horn and William Pao (see article on page 4247) ..... 4232

## Comments and Controversies

### ① Therapeutic Effect of Sentinel Lymph Node Biopsy in Melanoma Remains an Open Question

Phyllis A. Gimotty, Frank Yoon, Rachel Hammond, et al ..... 4236

## Original Reports

### EPIDEMIOLOGY

### ① Breast Cancer Risk in Female Survivors of Hodgkin's Lymphoma: Lower Risk After Smaller Radiation Volumes

Marie L. De Bruin, Judith Sparidans, Mars B. van't Veer, et al (see editorial on page 4229) ..... 4239

### THORACIC ONCOLOGY

### ① Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK

Alice T. Shaw, Beow Y. Yeap, Mari Mino-Kenudson, et al (see editorial on page 4232) ..... 4247

### ① Different Impact of Excision Repair Cross-Complementation Group 1 on Survival in Male and Female Patients With Inoperable Non-Small-Cell Lung Cancer Treated With Carboplatin and Gemcitabine

Bente Holm, Anders Mellempgaard, Torsten Skov, et al ..... 4254

### ① SOX Antibodies in Small-Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome: Frequency and Relation With Survival

Maarten J. Titulaer, Rinse Klooster, Marko Potman, et al ..... 4260

### ① Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Adjuvant Chemotherapy in Non-Small-Cell Lung Cancer: An Analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 Trial

Raymond W. Jang, Aurélie Le Maître, Keyue Ding, et al ..... 4268

(continued on following page)

*Journal of Clinical Oncology* (ISSN 0732-183X) is published 36 times a year, three times monthly, by the American Society of Clinical Oncology, 2318 Mill Road, Suite 800, Alexandria, VA 22314. Periodicals postage is paid at Alexandria, VA, and at additional mailing offices. Publication Mail Agreement Number 863289.

Editorial correspondence should be addressed to Daniel G. Haller, MD, *Journal of Clinical Oncology*, 2318 Mill Road, Suite 800, Alexandria, VA 22314. Telephone: (703) 797-1900; Fax: (703) 684-8720. E-mail: jco@asco.org. Internet: www.jco.org.

POSTMASTER: ASCO members send change of address to American Society of Clinical Oncology, 2318 Mill Road, Suite 800, Alexandria, VA 22314. Nonmembers send change of address to *Journal of Clinical Oncology* Customer Service, 2318 Mill Road, Suite 800, Alexandria, VA 22314.

2010 annual subscription rates, effective September 1, 2009: US and possessions: individual, \$578; single issue, \$40. International: individual, \$802; single issue, \$50. Institutions: Tier 1: \$817 US, \$1,129 Int'l; Tier 2: \$951 US, \$1,262 Int'l; Tier 3: \$1,373 US, \$1,674 Int'l; Tier 4: \$1,513 US, \$1,813 Int'l; Tier 5: contact JCO for a quote. See <http://www.jco.org/subscriptions/tieredpricing.shtml> for descriptions of each tier. Student and resident: United States and possessions: \$289; all other countries, \$401. To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the signature of program/residency coordinator on institution letterhead. Orders will be billed at individual rate until proof of status is received. Current prices are in effect for back volumes and back issues. Back issues sold in conjunction with a subscription rate are on a prorated basis. Subscriptions are accepted on a 12-month basis. Prices are subject to change without notice. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability. JCO Legacy Archive (electronic back issues from January 1983 through December 1998) is also available; please inquire.

- ① **Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer**  
George R. Blumenschein Jr, Ulrich Gatzemeier, Frank Fossella, et al ..... 4274

#### RADIATION ONCOLOGY

- ① **Validation of Lysyl Oxidase As a Prognostic Marker for Metastasis and Survival in Head and Neck Squamous Cell Carcinoma: Radiation Therapy Oncology Group Trial 90-03**  
Quynh-Thu Le, Jonathan Harris, Anthony M. Magliocco, et al ..... 4281

#### BREAST CANCER

- ① **Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial**  
Lajos Pusztai, Jong-Hyeon Jeong, Yun Gong, et al ..... 4287

#### DIAGNOSTICS

- ① **Chromogranin-A and N-Terminal Pro-Brain Natriuretic Peptide: An Excellent Pair of Biomarkers for Diagnostics in Patients With Neuroendocrine Tumor**  
Catharina M. Korse, Babs G. Taal, Cornelis A. de Groot, et al ..... 4293

#### GENITOURINARY CANCER

- Prostate Cancer–Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era**  
Andrew J. Stephenson, Michael W. Kattan, James A. Eastham, et al ..... 4300

- ① **Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy**  
Matthew R. Cooperberg, Shiro Hinotsu, Mikio Namiki, et al ..... 4306

- Prospective Study of [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Staging of Muscle-Invasive Bladder Carcinoma**  
Adam S. Kibel, Farrokh Dehdashti, Matthew D. Katz, et al ..... 4314

- Three-Dimensional Prostate Mapping Biopsy Has a Potentially Significant Impact on Prostate Cancer Management**  
Gary Onik, Matthew Miessau, and David G. Bostwick ..... 4321

- Quality of Surveillance for Stage I Testis Cancer in the Community**  
Hua-yin Yu, Rodger A. Madison, Claude M. Setodji, et al ..... 4327

#### GASTROINTESTINAL CANCER

- Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Recombinant Human Intestinal Trefoil Factor Oral Spray for Prevention of Oral Mucositis in Patients With Colorectal Cancer Who Are Receiving Fluorouracil-Based Chemotherapy**  
Douglas E. Peterson, Nicholas P. Barker, Lilia I. Akhmadullina, et al ..... 4333

- ① **Predictive Capacity of Three Comorbidity Indices in Estimating Mortality After Surgery for Colon Cancer**  
Robert B. Hines, Chakrapani Chatla, Harvey L. Bumpers, et al ..... 4339

#### PALLIATIVE AND SUPPORTIVE CARE

- Distress in Older Patients With Cancer**  
Arti Hurria, Daneng Li, Kurt Hansen, et al ..... 4346

#### HEMATOLOGIC MALIGNANCIES

- Prognostic Implications of *NOTCH1* and *FBXW7* Mutations in Adults With T-Cell Acute Lymphoblastic Leukemia Treated on the MRC UKALLXII/ECOG E2993 Protocol**  
Marc R. Mansour, Maria L. Sulis, Veronique Duke, et al ..... 4352

**Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies**

Owen A. O'Connor, Steven Horwitz, Paul Hamlin, et al ..... 4357

① **Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma**

Niels S. Andersen, Lone B. Pedersen, Anna Laurell, et al ..... 4365

① **Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma**

Ranjana Advani, Andres Forero-Torres, Richard R. Furman, et al ..... 4371

① **Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia**

Wolfgang U. Knauf, Toshko Lissichkov, Ali Aldaoud, et al ..... 4378

**PEDIATRIC ONCOLOGY**

① **Early and Late Therapy Response Assessment With [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter Trial**

Christian Furth, Ingo G. Steffen, Holger Amthauer, et al ..... 4385

① **Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia**

Sima Jeha, Bassem Razzouk, Michael Rytting, et al ..... 4392

**HEALTH SERVICES AND OUTCOMES**

**Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?**

Elizabeth A. Richey, E. Alison Lyons, Jonathan R. Nebeker, et al ..... 4398

**PHASE I AND CLINICAL PHARMACOLOGY**

① **Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity**

Nielka P. van Erp, Karel Eechoute, Astrid A. van der Veldt, et al ..... 4406

① **Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study**

Stephen Leong, Roger B. Cohen, Daniel L. Gustafson, et al ..... 4413

**Review Article**

**Targeting Signal Transducer and Activator of Transcription Signaling Pathway in Leukemias**

Mustafa Benekli, Heinz Baumann, and Meir Wetzler ..... 4422

**Special Article**

**Project Zero Delay: A Process for Accelerating the Activation of Cancer Clinical Trials**

Razelle Kurzrock, Susan Pilat, Marcel Bartolazzi, et al ..... 4433

**e.Diagnosis in Oncology**

**Hodgkin's Lymphoma With Digital Clubbing**

Matthew J. Goodyer, Marie-Claire Cronin, Dawn G. Ketsitlile, et al ..... e95

**Response to a Novel Multitargeted Tyrosine Kinase Inhibitor Pazopanib in Metastatic Merkel Cell Carcinoma**

Matthew Davids, Amanda Charlton, Swee-Siang Ng, et al ..... e97

**e Correspondence**

**High Rate of Febrile Neutropenia in Patients With Operable Breast Cancer Receiving Docetaxel and Cyclophosphamide**

Derrick Soong, Reem Haj, Mova G. Leung, et al ..... e101

**Breast Cancer Patients Unknowingly Dosing Themselves With Estrogen by Using Topical Moisturizers**

Adrienne C. Olson, John S. Link, James R. Waisman, et al ..... e103

**“Sufficient Life Expectancy”: An Amazing Inclusion Criterion in Cancer Phase II-III Trials**

Nicolas Penel, Stéphanie Clisant, Jean-Louis Lefebvre, et al ..... e105

**Long-Term Response in Primary Renal Cancer to Sequential Antiangiogenic Therapy**

Nicholas J. Vogelzang, Wolfram Samlowski, and Alan Weissman ..... e106

**2009 Version of the Chompret Criteria for Li Fraumeni Syndrome**

Julie Tinat, Gaele Bougeard, Stéphanie Baert-Desurmont, et al ..... e108

**Reply to J. Tinat et al**

Kelly D.F. Gonzalez, Carolyn H. Buzin, Jeffrey N. Weitzel, et al ..... e110

**Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial**

Lawrence C. Panasci ..... e111

**Reply to L.C. Panasci**

Judith Hugh, John Hanson, Maggie Cheang, et al ..... e112

**Also in This Issue**

**Information for Subscribers**

**Information for Contributors**

**Manuscript Submission Checklist**

**Current Abstracts**

**Forthcoming Reports**



Supplementary information available at [www.jco.org](http://www.jco.org)



Diagnosis in Oncology and Correspondence available at [www.jco.org](http://www.jco.org)